| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2839021 | Trends in Molecular Medicine | 2010 | 8 Pages |
Abstract
Therapies for multiple sclerosis (MS) reduce the relapse rate but are unable to stop neurological decline. Here, we evaluate the potential of leukemia inhibitory factor (LIF) as a novel therapeutic in diseases with a neurodegenerative and inflammatory component, such as MS. LIF, which can be a proinflammatory cytokine, can also modulate the immune response in a beneficial way. Recent evidence demonstrates a crucial role of LIF in neuroprotection and axonal regeneration as well as the prevention of demyelination. Finally, LIF is an important survival factor for stem cells and neuronal precursors. Therefore, we propose that LIF is a potential therapeutic candidate for MS.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Helena Slaets, Jerome J.A. Hendriks, Piet Stinissen, Trevor J. Kilpatrick, Niels Hellings,